Real-world comparison of chemo-immunotherapy and chemotherapy alone in the treatment of extensive-stage small-cell lung cancer.

Fiche publication

Date publication

novembre 2024

Journal

Respiratory medicine and research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FOUCHER Pascal , Pr GHIRINGHELLI François , Pr BONNIAUD Philippe

Tous les auteurs :
Lamy D, Mouillot P, Mariet A, Barnestein R, Quilot F, Fraisse C, Ghiringhelli F, Bonniaud P, Zouak A, Foucher P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39033607

Résumé

Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma responsible for 200,000 deaths per year worldwide. Platinum-etoposide-based chemotherapy has been the standard of treatment for the past 40 years, with an overall survival of 10 months. Since 2019, the addition of immunotherapy (atezolizumab or durvalumab) to chemotherapy has become the standard of care for first-line treatment of extensive-stage SCLC following the demonstration of an improvement in overall survival in phase 3 studies. We aimed to evaluate the efficacy and safety of chemo-immunotherapy compared with chemotherapy alone in a "real-world" setting.